fosaprepitant dimeglumine in treating patients with nausea and vomiting caused by chemotherapy

Conditions: Breakthrough Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. purpose: this clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.

objectives: primary * to evaluate the efficacy and safety of fosaprepitant dimeglumine in patients with breakthrough chemotherapy-induced nausea and vomiting (cinv) after failing prophylactic antiemetic therapy. secondary * to evaluate toxicity and serious adverse events associated with this regimen in these patients. * to evaluate the ability of patients to tolerate oral intake. * to evaluate the health-related quality of life of patients treated with this regimen. * to evaluate specific side effects associated with this regimen, including pain sensation and/or soreness at the infusion site, headache, dizziness, and somnolence, in these patients . * to refine the study design for future phase ii and iii studies of rescue therapy for breakthrough cinv using various secondary endpoints. outline: patients receive chemotherapy in combination with a pre-defined standard 5-hydroxytryptamine-3 (5-ht3) antagonist or corticosteroid regimen with or without a benzodiazepine on day 1. if breakthrough nausea or vomiting occurs, patients then receive fosaprepitant dimeglumine iv once per standard administration guidelines. patients with treatment response may receive additional doses of oral aprepitant once on days 2 and 3. patients with persistent nausea/vomiting after 2 hours and who desire further treatment may receive standard rescue therapy with prochlorperazine, metoclopramide, or haloperidol with or without additional lorazepam until relief, at the discretion of the provider. patients complete a diary at baseline, and then at 2, 12, and 24 hours that includes a visual analogue scale (vas) for nausea; vas for sedation; and questions about emesis and retching frequency, headache, dizziness, somnolence, and ability to take food and liquids orally. patients also complete the functional living index-emesis quality of life survey at baseline and at 24 hours.

Eligibility criteria:
disease characteristics: * diagnosis of cancer * scheduled to receive inpatient chemotherapy containing at least moderately emetogenic agents * may be given for adjuvant, neoadjuvant, curative, or palliative intent * may be given orally, iv, or by continuous infusion on ≥ 1 day * scheduled to receive 5-ht3 receptor antagonist antiemetic (e.g., ondansetron, granisetron, palonosetron, dolasetron mesylate, or dexamethasone with or without a benzodiazepine) on the day of chemotherapy * self-report of at least mild nausea (for which the patient feels needs rescuing) or moderate nausea (a score of ≥ 2 on a 4-point likert scale) or has had ≥ 1 episode of emesis since receiving chemotherapy * no history of chronic nausea and/or vomiting (without chemotherapy), anticipatory nausea and/or vomiting, or emesis within 24 hours before chemotherapy * no symptomatic brain metastases patient characteristics: * able to understand english * not pregnant or nursing * negative pregnancy test * no clinical evidence of current or impending bowel obstruction (i.e., tumor pressing on the bowel) * no allergy or intolerance to study drugs prior concurrent therapy: * see disease characteristics * prior chemotherapy allowed * no aprepitant as prophylaxis or rescue treatment during the current course of chemotherapy (other than as a part of study therapy) * not scheduled to receive a dopamine antagonist after chemotherapy

Keywords: nausea and vomiting unspecified adult solid tumor, protocol specific